

| | Group | n | DENV-1 | DENV-2 | DENV-3 | DENV-4 |
|---|-------------------------|----|--------|--------|--------|--------|
| 1 | Anti-DENV seronegative* | 20 | <10 | <10 | <10 | <10 |
| 2 | Standard antisera^: | | | | | |
| | Anti-DENV-1 | 1 | 10 | <10 | <10 | <10 |
| | Anti-DENV-2 | 1 | <10 | 20 | <10 | <10 |
| | Anti-DENV-3 | 1 | <10 | <10 | 10 | <10 |
| | Anti-DENV-4 | 1 | <10 | <10 | <10 | 10 |
| 3 | Anti-JEV | 2 | <10 | <10 | <10 | <10 |
| 4 | Anti-MVEV | 2 | <10 | <10 | <10 | <10 |
| 5 | Anti-KUNV | 1 | <10 | <10 | <10 | <10 |
| 6 | Multitypic infection#: | | | | | |
| | DENV-2; DENV-1 | 1 | 10 | 80 | 10 | <10 |
| | DENV-1;DENV-3;DENV-2 | 1 | 160 | 80 | 80 | 20 |
| | DENV-2;DENV-1;DENV-4 | 1 | 80 | 320 | 40 | 20 |

* Individuals confirmed seronegative for anti-DENV by microneutralization and hemagglutination inhibition assay, with negative NS1 ELISA test. ^Standard DENV-1-4 antisera NIBSC 05/248 (National Institute for Biological Standards and Control [NIBSC], Potter's Bar, Hertfordshire, United Kingdom).# Individuals with well-defined (IgM/PCR positive) sequential DENV infection